Tools   Select Another Resource Report Type

http://www.nextprot.org/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on April 15,2025. Human protein knowledge platform. Knowledge platform for human proteins selects and filters high throughput data pertinent to human proteins from UniProtKB. Extends UniProtKB/Swiss-Prot annotations for human proteins to include several new data types.

Proper citation: neXtProt (RRID:SCR_008911) Copy   

•   Source: SciCrunch Registry

http://www.nitrc.org/projects/bnv/

Aa brain network visualization tool, which can help researchers to visualize structural and functional connectivity patterns from different levels in a quick, easy, and flexible way.

Proper citation: BrainNet Viewer (RRID:SCR_009446) Copy   

•   Source: SciCrunch Registry

http://services.ceon.pl/cermine/index.html

Java library and a web service for extracting metadata and content from scientific articles in born-digital form. The system analyses the entire content of a PDF file containing a publication and attempts to extract information such as: the title of the article, journal information (title, etc.), bibliographic information (volume, issue, page numbers, etc.), authors and affiliations, keywords, abstract, bibliographic references and structured sections hierarchy.

Proper citation: CERMINE (RRID:SCR_008993) Copy   

•   Source: SciCrunch Registry

http://www.researchgate.net/conferences/

Listing of scientific conferences from across the globe and provides you with the tools to get the most out of them: post, follow, discuss - all for free.

Proper citation: ResearchGate: Research Conferences (RRID:SCR_006487) Copy   

•   Source: SciCrunch Registry

http://www.biolayout.org

BioLayout Express3D is a powerful new tool for the visualization and analysis of networks derived from biological systems. Network-based approaches are becoming increasing popular for the analysis of ''omics and other high dimensional data. Networks can be produced from a wide variety of biological relationships, such as interactions between individuals, disease transmission, sequence similarity, metabolic pathways, protein interactions, pathways, regulatory cascades, gene expression, etc. BioLayout Express3D has been specifically designed for visualization, clustering and analysis of large network graphs in two- and three-dimensional space derived primarily, but not exclusively, from biological data. Sponsors: This resource is supported by BBSRC (BB / F003722 / 1) and the Wellcome Trust (GR077040RP). Keywords: Biology, Tool, Software, visualization, Analysis, Network, Biological, System, Dimentional, Data, Disease, Transmission, Sequence, Metabolic, Pathway, Protein, Interaction, Gene, Expression, Clustering, Analysis,

Proper citation: BioLayout Express 3D (RRID:SCR_007179) Copy   

•   Source: SciCrunch Registry

http://www.nlm.nih.gov/research/umls/

Database of key terminology, classification and coding standards, and associated resources to promote creation of more effective and interoperable biomedical information systems and services, including electronic health records. This set of files and software brings together many health and biomedical vocabularies and standards to enable interoperability between computer systems. Users can use the UMLS to enhance or develop applications, such as electronic health records, classification tools, dictionaries and language translators. The UMLS has three tools, which we call the Knowledge Sources: * Metathesaurus: Terms and codes from many vocabularies, including CPT, ICD-10-CM, LOINC, MeSH, RxNorm, and SNOMED CT * Semantic Network: Broad categories (semantic types) and their relationships (semantic relations) * SPECIALIST Lexicon and Lexical Tools: Natural language processing tools We use the Semantic Network and Lexical Tools to produce the Metathesaurus. Metathesaurus production involves: * Processing the terms and codes using the Lexical Tools * Grouping synonymous terms into concepts * Categorizing concepts by semantic types from the Semantic Network * Incorporating relationships and attributes provided by vocabularies * Releasing the data in a common format Although we integrate these tools for Metathesaurus production, you can access them separately or in any combination according to your needs. The UMLS Terminology Services (UTS) provides three ways to access the UMLS: Web Browsers, Local Installation, and Web Services APIs.

Proper citation: Unified Medical Language System (RRID:SCR_006363) Copy   

•   Source: SciCrunch Registry

http://www.ninds.nih.gov/news_and_events/proceedings/20101217-NEXT.htm

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on June 26,2022. A unique clinical trial network open to studies of more than 400 neurological diseases, allowing investigators to more efficiently pursue new therapies based on scientific opportunity. The network has a centralized IRB serving 25 sites, which will allow trials to move faster, without the need to coordinate IRBs at each individual site. It is not necessary to be part of the NeuroNEXT infrastructure to propose and conduct a study within the network. The Network for Excellence in Neuroscience Clinical Trials, or NeuroNEXT, was created to conduct studies of treatments for neurological diseases through partnerships with academia, private foundations, and industry. The network is designed to expand the National Institute of Neurological Disorders and Stroke''s (NINDS) capability to test promising new therapies, increase the efficiency of clinical trials before embarking on larger studies, and respond quickly as new opportunities arise to test promising treatments for people with neurological disorders. The NeuroNEXT program aims to: * Provide a robust, standardized, and accessible infrastructure to facilitate rapid development and implementation of protocols in neurological disorders affecting adult and/or pediatric populations. The network includes multiple Clinical Sites, one Clinical Coordinating Center (CCC) and one Data Coordinating Center (DCC). * Support scientifically sound, possibly biomarker-informed, Phase II clinical trials that provide data for clear go/no-go decisions. * Energize and mobilize federal, industry, foundations and patient advocacy partners by leveraging existing relationships between NINDS and NeuroNEXT to organize high impact Phase II clinical trials for neurological disorders. * Expand the pool of experienced clinical investigators and research staff who are prepared to be leaders of multicenter clinical research trials. * Working with NeuroNEXT is a cooperative venture between NINDS, the NeuroNEXT network and the applicant.

Proper citation: NeuroNEXT (RRID:SCR_006760) Copy   

•   Source: SciCrunch Registry

http://www.chemservice.com

Chem Service, Inc. offers the convenience, cost savings and reliability of 1,000 Certified Standards Grade Organic Chemicals at your fingertips with our Organic Mini Stockroom Kit. Whether your lab is big or small, disposal fees are a concern. The Organic Mini-stockroom offers you the ability to have 1000 different chemicals at quantities ranging from 100mg to 10gm; thus, reducing disposal costs. Over 95% of their neat Standards Grade materials have a purity of 98.0% or greater, and have been analyzed by three or more (where feasible) independent methods of analysis. These do not require purity corrections when preparing a solution for use with EPA methods. Their more than 13,000 organic and inorganic standards, and solutions, support EPA Methods, ASTM Methods, State UST Methods, Air monitoring Methods, and International Methods. They offer explosive residue standards, PCB congeners, petroleum hydrocarbon standards for the petrochemical industry, pesticide standards, FAME, and vitamin standards for food analysis. Suited for identification of unknowns, product screening, optimal chemical selection and small scale chemical reactions, the O-1000A Organic Ministockroom Kit was designed for laboratories with broad chemical classification and indentification needs. Chem Service, Inc. is registered by ABS Quality Evaluations, Inc., to the internationally recognized requirements of ISO 9001 for design, development, production, distribution and servicing of organic neat and synthetic reference materials.

Proper citation: Chem Service, Inc. (RRID:SCR_008380) Copy   

•   Source: SciCrunch Registry

http://harvester.fzk.de/harvester/

Harvester is a Web-based tool that bulk-collects bioinformatic data on human proteins from various databases and prediction servers. It is a meta search engine for gene and protein information. It searches 16 major databases and prediction servers and combines the results on pregenerated HTML pages. In this way Harvester can provide comprehensive gene-protein information from different servers in a convenient and fast manner. As full text meta search engine, similar to Google trade mark, Harvester allows screening of the whole genome proteome for current protein functions and predictions in a few seconds. With Harvester it is now possible to compare and check the quality of different database entries and prediction algorithms on a single page. Sponsors: This work has been supported by the BMBF with grants 01GR0101 and 01KW0013.

Proper citation: Bioinformatic Harvester IV (beta) at Karlsruhe Institute of Technology (RRID:SCR_008017) Copy   

•   Source: SciCrunch Registry

https://www.medizin.uni-tuebingen.de/en/Students/Institutes/Medical+Psychology.html

The Institute of Medical Psychology and Behavioral Neurobiology in Germany is an institutional portal established at the Faculty of Medicine of the University of Tbingen in 1993. With the assignment of the chair for Medical Psychology and Medical Sociology to Professor Birbaumer the educational task became the instruction of medical students in Medical Psychology and Medical Sociology. Christoph-Dornier-Center of Clinical Psychology at the University of Tobingen Medical Faculty In March 2001, a new institute of the Christoph Dornier Foundation was opened under the direction of Prof. Niels Birbaumer. The aim of this institute is to advance research in behavioral neurobiology and behavioral medicine. The results of the research should be directly translated into treatments. The emphasis in Tbingen is on the treatment of chronic pain and intractable epilepsy, using a combination of biofeedback training and behavioral therapy. Even though a positive effect of biofeedback has been proven in many controlled studies, the method is still far from being accepted in everyday clinical practice. The outpatient department in Tbingen intends to enable access to this treatment to a wider population of patients. Magnetoencephalography(MEG)-Center The MEG-Center (established 1997) is a central research facility at the University of Tbingen. The Center is operated by the Institute of medical psychology and behavioural Neurobiology and hosts a whole-head 151-channel system built by VSMMedtech (www.vsmmedtech.com). In early 2006 in addition to the wholehead MEG an additional special purpose MEG system will be installed in Tbingen (funded by the DFG and Land Baden Wrttemberg). This MEG is dedicated to the investigation of fetal brain signals in utero (fMEG) . The fMEG will be installed at the University Woman Clinic and operated by the staff of the MEG center. This is the first dedicated fMEG system in Europe. Some content on the website is only in German.

Proper citation: Institute of Medical Psychology and Behavioral Neurobiology, University of Tbingen (RRID:SCR_008011) Copy   

•   Source: SciCrunch Registry

http://alzheimers.med.umich.edu/

An Alzheimer's disease center which aims to conduct and promote research on Alzheimer's disease and enhance public and professional understanding of dementia through education and outreach efforts. The MADC promotes clinical research on memory and aging which involves the direct use of research volunteers, biomarkers, and other clinical data collected through the University of Michigan Memory and Aging Project.

Proper citation: Michigan Alzheimer's Disease Center (RRID:SCR_008773) Copy   

•   Source: SciCrunch Registry

http://www.parkinsoninfo.org

THIS RESOURCE IS NO LONGER IN SERVICE, documented on May 18th, 2016. A foundation that was founded in 2001, and sponsors academic centers throughout the US. The MIchael Stern Parkinson's Research Foundation focuses its efforts mainly on finding the causes of the disease, finding effective treatments, and discovering a cure for the disease. The foundation is notably looking into dopamine and its effects on neural connections, as well its possibility to be used for treatment.
Dr. Greengard has assembled a close knit group of more than 25 outstanding scientists who are focused on translating the fundamental understandings about the dopamine system into new treatments for Parkinson's. The core team of researchers is based at the Stern Foundation laboratory on the campus of The Rockefeller University interacts continually with collaborators from the United Kingdom, France, Sweden, Italy, Japan and Korea. This global presence ensures that no promising research lead is overlooked, and that progress can be made on multiple fronts simultaneously. As the Foundation grew it was able to expand its support for critical neurological research to two other institutions, Harvard University's McLean Hospital, where we support the research of Dr. Ole Isacson whose research lab, The Stern Center for Neuroregeneration Research is using gene therapy to protect the most vulnerable neurons in PD models; and the Institute for Neurodegenerative Disorders, where Yale Professors Dr. Ken Marek and Dr. John Seibyl are developing novel tools for early detection and monitoring of Parkinson's disease by studying physiologic, biochemical and neuroimaging biomarkers for non-dominergic manifestations of Parkinsonism. :NIF thanks the Parkinson's Disease Foundation, http://www.pdf.org for their referral of this resource to us.

Proper citation: Michael Stern Parkinsons Research Foundation (RRID:SCR_008098) Copy   

•   Source: SciCrunch Registry

http://www.nimh.nih.gov/funding/clinical-trials-for-researchers/practical/step-bd/index.shtml

A long-term outpatient study designed to find out which treatments, or combinations of treatments, are most effective for treating episodes of depression and mania and for preventing recurrent episodes in people with bipolar disorder. This study has been completed. (2005) STEP-BD is evaluating all the best-practice treatment options used for bipolar disorder: mood-stabilizing medications, antidepressants, atypical antipsychotics, and psychosocial interventions - or talk therapies - including Cognitive Behavioral Therapy, Family-focused Therapy, Interpersonal and Social Rhythm Therapy, and Collaborative Care (psychoeducation). There are two kinds of treatment pathways in STEP-BD, and participants may have the opportunity to take part in both. The medications and psychosocial interventions provided in these pathways are considered among the best choices of treatment for bipolar disorder in everyday clinical practice. In the Best Practice Pathway, participants are followed by a STEP-BD certified doctor and all treatment choices are individualized. Everyone enrolled in STEP-BD may participate in this pathway. Participants and their doctors work together to decide on the best treatment plans and to change these plans if needed. Also, anyone who wishes to stay on his or her current treatment upon entering STEP-BD may do so in this pathway. Adolescents and adults age 15 years and older may participate in the Best Practice Pathway. For adults age 18 and older, another way to participate is in the STEP-BD Randomized Care Pathways. Depending on their symptoms, participants may be offered treatment in one or more of these pathways during the course of the study. The participants remain on mood-stabilizing medication. However, because doctors are uncertain which of several treatment strategies work best for bipolar disorder, another medication and/or talk therapy may be added. Each Randomized Care Pathway involves a different set of these additional treatments. Unlike in the Best Practice Pathway, the participants in the Randomized Care Pathways are randomly assigned to treatments. Also, in some cases, neither the participant nor the doctor will be told which of the different medications is being added. This is called a double-blind study and is done so that the medication effects can be evaluated objectively, without any unintended bias that may come from knowing what has been assigned. Participants will not be assigned medications that they have had bad reactions to in the past, that they are strongly opposed to, or that the doctor feels are unsuitable for them. The medication(s) participants may be randomly assigned to in the Randomized Care Pathways are free of charge. There are other treatment options for participants if they do not respond well to the treatment assigned to them. Also, participants may return to the Best Practice Pathway at any time. About 1,500 individuals will be enrolled in at least one Randomized Care Pathway during their period of participation in STEP-BD. It is important to note that STEP-BD provides continuity of care. For example, if a participant starts out in the Best Practice Pathway and later chooses to enter one of the Randomized Care Pathways, he or she continues with the same STEP-BD doctor and treatment team. Then, after completing the Randomized Care Pathway, the participant may return to the Best Practice Pathway for ongoing, individually-tailored treatment. Follow the link to view study info at Clinicaltrials.gov, http://www.clinicaltrials.gov/ct/show/NCT00012558?order=1

Proper citation: Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) (RRID:SCR_008844) Copy   

•   Source: SciCrunch Registry

http://www.neurosci.umn.edu/

The graduate program in neuroscience at the University of Minnesota is a large, multidisciplinary program consisting of over 100 faculty members from all parts of the University of Minnesota, over 25 departments from over 10 colleges. The multidisciplinary nature of the Ph.D. program is one of its most significant strengths.

Proper citation: University of Minnesota Graduate Program in Neuroscience (RRID:SCR_007516) Copy   

•   Source: SciCrunch Registry

http://www.ideal.force.cs.is.nagoya-u.ac.jp/IDEAL/

IDEAL, Intrinsically Disordered proteins with Extensive Annotations and Literature, is a collection of knowledge on experimentally verified intrinsically disordered proteins (IDPs) or intrinsically disordered regions (IDRs). IDEAL contains manually curated annotations on IDPs in locations, structures, and functional sites such as protein binding regions and posttranslational modification sites together with references and structural domain assignments. Protean segment One of the unique phenomena seen in IDPs is so-called the coupled folding and binding, where a short flexible segment can bind to its binding partner with forming a specific structure to act as a molecular recognition element. IDEAL explicitly annotates these regions as protean segment (ProS) when unstructured and structured information are both available in the region. Access to the data All the entries are tabulated in the list and individual entries can be retrieved by using the search tool at the upper-right corner in this page. IDEAL also provides the BLAST search, which can find homologs in IDEAL. All the information in IDEAL can be downloaded in the XML file.

Proper citation: IDEAL - Intrinsically Disordered proteins with Extensive Annotations and Literature (RRID:SCR_006027) Copy   

•   Source: SciCrunch Registry

http://www.pathbase.net/

Database of histopathology photomicrographs and macroscopic images derived from mutant or genetically manipulated mice. The database currently holds more than 1000 images of lesions from mutant mice and their inbred backgrounds and further images are being added continuously. Images can be retrieved by searching for specific lesions or class of lesion, by genetic locus, or by a wide set of parameters shown on the Advanced Search Interface. Its two key aims are: * To provide a searchable database of histopathology images derived from experimental manipulation of the mouse genome or experiments conducted on genetically manipulated mice. * A reference / didactic resource covering all aspects of mouse pathology Lesions are described according to the Pathbase pathology ontology developed by the Pathbase European Consortium, and are available at the site or on the Gene Ontology Consortium site - OBO. As this is a community resource, they encourage everyone to upload their own images, contribute comments to images and send them their feedback. Please feel free to use any of the SOAP/WSDL web services. (under development)

Proper citation: Pathbase (RRID:SCR_006141) Copy   

•   Source: SciCrunch Registry

http://www.cerep.fr/Cerep/Users/pages/ProductsServices/InVitro.asp

Cerep offers a panel of over 630 validated in vitro pharmacological assays that cover a broad range of targets including receptors, ion channels, transporters, enzymes and second messengers. These assays are used to identify lead compounds, to define mechanism of action, and to identify off-target activities. All assays are available on an ad hoc basis. At any time, clients can select one or more assays to be tested against one or more compounds at one or more concentrations. In addition to ad hoc access, client specific and Cerep profiles are available. Client specific profiles can be adapted using any of the over 630 Cerep assays. Standard Profiles are designed by Cerep and available to all clients. The Standard Profiles are a rapid and cost effective way of prioritizing the most promising compounds in the lead selection process. Benefiting from increased efficiency generated from optimized processes, Cerep is happy to expand custom made profiles clients can design at set prices. While offering more flexibility, clients are able to select among predefined lists of functional GPCR, kinase and binding assays. Keywords: In vitro, Pharmacology, Assay, Target, Receptor, Ion channel, Transporter, Enzyme, Mechanism, Hoc, Compound, Kinase, GPCR, Secondary messenger,

Proper citation: CEREP: In Vitro Pharmacology (RRID:SCR_007233) Copy   

•   Source: SciCrunch Registry

http://www.vistrails.org/

Open-source scientific workflow and provenance management system that provides support for simulations, data exploration and visualization. It was designed to manage these rapidly-evolving workflows. VisTrails has a comprehensive provenance infrastructure that maintains detailed history information about the steps followed and data derived in the course of an exploratory task: VisTrails maintains provenance of data products, of the workflows that derive these products and their executions. This information is persisted as XML files or in a relational database, and it allows users to navigate workflow versions in an intuitive way, to undo changes but not lose any results, to visually compare different workflows and their results, and to examine the actions that led to a result. It also enables a series operations and user interfaces that simplify workflow design and use, including the ability to create and refine workflows by analogy and to query workflows by example. VisTrails supports the creation and execution of workflows. It allows the combination of loosely-coupled resources, specialized libraries, grid and Web services. The released version comes with support for several packages including, VTK, Image Magick, Web Services, and pylab. You can also download packages contributed by users, as well as create your own packages/modules. Workflows can be run interactively, through the VisTrails GUI, or in batch using a VisTrails server. VisTrails is written in Python and it uses the multi-platform Qt library for its user interface. It runs on Mac, Linux and Windows. Provenance-rich results derived by VisTrails can be included in LaTeX, Wiki, Microsoft Word and PowerPoint documents.

Proper citation: VisTrails (RRID:SCR_006261) Copy   

•   Source: SciCrunch Registry

http://www.ibioseminars.org/

iBioSeminars offers: * Free, on-demand lectures: Many universities/colleges have limited access to high profile leaders in biological research. Our goal is to add 15-20 seminars per year, of similar quality to outstanding lectures that are currently in this library. Access, through web streaming or download, is completely free-of-charge. * Targeting a broad audience: iBioSeminars start with an extended introduction, making them accessible to non-specialists and students, and then progress to cover current research. Senior scientists and students can view and enjoy these lectures. * Education: iBioSeminars are being used by undergraduate and graduate teachers to augment their classroom material. We have now added an education component to this web site (including lecture notes, questions/answers and short video clips for teaching). * International communication: iBioSeminars have viewers in 115 countries and they are being internally promoted in several countries as an educational tool and scientific resource. * Goodwill: Lecturers generously donate their time to prepare these lectures. The project, largely funded by HHMI, is a grass roots efforts with time invested by several individuals at UCSF, HHMI and ASCB.

Proper citation: iBioSeminars (RRID:SCR_005848) Copy   

•   Source: SciCrunch Registry

http://cgf.nci.nih.gov

With remarkable advances in genomic technologies, the National Cancer Institute established the Core Genotyping Facility (CGF) to investigate the contribution of germline genetic variation to cancer susceptibility and outcomes. Working in concert with epidemiologists, biostatisticians and basic research scientists in the intramural research program, the CGF has developed the capacity to conduct genome-wide association studies and candidate gene approaches to identify the heritable determinants of various forms of cancer. In order to ensure the accuracy and timely completion of all CGF provided operations, the following Information Systems were developed. While the investigator does not have direct access to these systems, their availability to CGF staff members greatly aids in their querying and reporting capabilities. In turn this provides benefit to the investigator by providing the most up to date reporting possible. The Core Genotyping Facility (CGF) offers a wide variety of sample preparation and genotyping operations. All samples received must meet minimum requirements and are taken through the Sample Handling pipeline prior to completing any genotyping. The Sample Handling pipeline includes DNA quantification and genetic fingerprinting. Also offered are Whole Genome Amplification (WGA) assays, to get the most yield out of low quantity DNA samples. Theirr genotyping products cover a wide-range of assay sizes. The CGF operates the Illumina BeadLab system which supports Illumina assay technologies including the whole genome genotyping Infinium assays, custom GoldenGate OPA assays, and Custom Infinium (iSelect) assays. In addition, the CGF offers Affymetrix GeneChip arrays and uniplex TaqMan genotyping. Sponsors: CGF is supported by the SAIC-Frederick. :Keywords: Genomic, Technology, Cancer, Genotyping, Germline, Genetic, Epidemiologist, Biostatistician, Research, Gene, Assay, Genotype, Pipeline, Genome, DNA, :

Proper citation: Core Genotyping Facility (RRID:SCR_008438) Copy   

•   Source: SciCrunch Registry